Ultima announces UG 100™ and reveals disruptive cost and accuracy profile to enable the era of the $100 genome and beyond

Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, announced the full commercial availability of the UG 100TM sequencer today. The UG 100TM system, Ultima’s first commercial product, leverages Ultima’s unique sequencing architecture featuring an open silicon wafer substrate to replace the traditional flow cells and enable the $100 genome and beyond.

Our goal when designing our sequencing architecture and the UG 100TM was to provide a technology platform that enables a scalable roadmap beyond the $100 genome, ultra-high-output without the limitations of batching, and extreme accuracy in applications for which it is most needed, ... We are excited to be launching the UG 100TM and helping the genomics community usher in the era of the $100 genome and beyond.

Gilad Almogy, founder and CEO of Ultima Genomics

The UG 100TM, now available for purchase, features Ultima’s proprietary wafer-based sequencing substrate with flexible, non-kit-based sequencing reagent cartridges and a novel sequencing chemistry. Unlike more traditional kit-based approaches, this unique architecture allows built-in robotics, enabling full 24/7 run automation for improved flexibility with limited user touchpoints. The UG 100TM system also leverages recent advancements in machine learning to improve base calling and variant calling algorithms for improved accuracy and performance.

Select key features of the UG 100 system include:

  • Low-cost reagents. One wafer and reagent configuration for $2,000 delivers 6-8 B reads and an expected average read length of 300 base pairs or an output of up to 2.4 Tb per wafer. This scalable configuration enables the $100 genome at an industry-leading price of $1.00 per GB or $0.30 per million reads.
  • Flexibility and automation. Dual wafer sequencing run output of up to 4.8 Tb at a run time of 14 hours, or less than 12 hours for shorter read applications, and 6-8 B reads per wafer reduces the need for complex batching while maintaining industry-leading price per Gb across a wide range of sample volume. On-tool robotics and automated run kick-off for full 24/7 operation and weekend sequencing operations with the standard 5-day work week.
  • Clinical quality genomes. Unique flow-based chemistry and rapid advancements in AI-based base and variant calling enable accuracy on par with other platforms with SNV F1 of 99.8 % and INDEL F1 of 99.4 %. The updated GIAB reference data set is available on Ultima’s website.
  • Extreme accuracy for rare event applications. Industry-leading SNV accuracy profile and extreme accuracy technology with ppmSEQTM.
  • High production instrument. Capable of delivering 20 wafers per week and up to 20,000 genomes per year. For shorter read applications, the UG 100TM delivers 28 wafers per week.

Introducing ppmSeqTM – Q60 raw read accuracy for base substitutions

Today, the Company is also introducing ppmSeqTM, a disruptive new mode for extreme raw read accuracy in calling single nucleotide variants (SNVs). ppmSeqTM is a new proprietary feature enabled by Ultima’s unique approach that dramatically improves the raw read accuracy of calling SNVs by removing sample errors introduced upstream of the sequencing workflow. Using this feature, users of Ultima’s sequencing system can achieve raw error rates for SNVs as low as 1 in a million or Q60 levels of accuracy. Importantly, this feature is native to Ultima’s sequencer and does not require additional costs, extra reagents, or workflow modifications.

With the launch of the UG 100TM system, Ultima looks to enable the next wave of biology powered by low-cost sequencing data generation. The UG 100TM system is currently available to order.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Ultima Genomics, Inc.. (2024, February 26). Ultima announces UG 100™ and reveals disruptive cost and accuracy profile to enable the era of the $100 genome and beyond. News-Medical. Retrieved on April 16, 2024 from https://www.news-medical.net/news/20240226/Ultima-announces-UG-100e284a2-and-reveals-disruptive-cost-and-accuracy-profile-to-enable-the-era-of-the-24100-genome-and-beyond.aspx.

  • MLA

    Ultima Genomics, Inc.. "Ultima announces UG 100™ and reveals disruptive cost and accuracy profile to enable the era of the $100 genome and beyond". News-Medical. 16 April 2024. <https://www.news-medical.net/news/20240226/Ultima-announces-UG-100e284a2-and-reveals-disruptive-cost-and-accuracy-profile-to-enable-the-era-of-the-24100-genome-and-beyond.aspx>.

  • Chicago

    Ultima Genomics, Inc.. "Ultima announces UG 100™ and reveals disruptive cost and accuracy profile to enable the era of the $100 genome and beyond". News-Medical. https://www.news-medical.net/news/20240226/Ultima-announces-UG-100e284a2-and-reveals-disruptive-cost-and-accuracy-profile-to-enable-the-era-of-the-24100-genome-and-beyond.aspx. (accessed April 16, 2024).

  • Harvard

    Ultima Genomics, Inc.. 2024. Ultima announces UG 100™ and reveals disruptive cost and accuracy profile to enable the era of the $100 genome and beyond. News-Medical, viewed 16 April 2024, https://www.news-medical.net/news/20240226/Ultima-announces-UG-100e284a2-and-reveals-disruptive-cost-and-accuracy-profile-to-enable-the-era-of-the-24100-genome-and-beyond.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.